miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo

Hu, Guoqing; Chen, Dao-Jin; Li, Xiaorong; Yang, Kaiyan; Wang, Hongxian; Wu, Wei

doi:10.4161/cbt.10.2.12186

Cited by 107 publications

(105 citation statements)

References 35 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…Since miR-143 inhibited HeLa cell proliferation in vitro, we further assessed its effect on tumor formation in vivo. HeLa cells (5x10 6 ) were first transfected with pre-miR-143, pre-anti-miR-143 or control miRNA precursor, respectively, and the stable cell lines were selected by puromycin. The three cell lines were injected subcutaneously into the flanks of nude mice.…”

Section: Mir-143 Inhibits Hela Cell Proliferation and Promotes Apoptomentioning

confidence: 99%

“…All procedures involving mice were approved by the Central South University Animal Management Committee. HeLa cells (5x10 6 ) transfected with pre-miR-143, pre-anti-miR-143 or control miRNA precursor were injected subcutaneously into the flanks of nude mice (6 mice/group). The volume (V) of the implanted tumor was measured every 3rd day with a vernier caliper, and the tumor sizes were estimated using the formula: V (mm 3 ) = length x width 2 x 0.5.…”

Section: Quantitative Real-time Pcr and Rt-pcrmentioning

confidence: 99%

“…In fact, numerous studies have shown that miRNAs are involved in cell proliferation, apoptosis (1), differentiation (2), reproduction (3) and cancer (4). In addition, miRNAs also function as potential oncogenes or tumor-suppressor genes involved in tumor development and progression, and this has been well documented in many tumors, including pancreatic (5), colon (6), gastric (7), breast (8), liver (9), lung (10) and nasopharyngeal cancer (11).…”

mentioning

confidence: 99%

See 2 more Smart Citations

miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2

Liu

Guo

et al. 2011

Mol Med Report

View full text Add to dashboard Cite

show abstract

Section: Mir-143 Inhibits Hela Cell Proliferation and Promotes Apoptomentioning

confidence: 99%

Section: Quantitative Real-time Pcr and Rt-pcrmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2

Liu

Guo

et al. 2011

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…miR‐133b was first considered to be a muscle‐specific microRNA, however, some recent research revealed that there was significant correlation between abnormal expression of miR‐133b and tumorigenesis. miR‐133b may affect the ability of tumor cell proliferation, apoptosis, and invasion by regulating the expression of different target genes 8, 9. The abnormal expression of miRNA may act as a potential prognostic factor.…”

Section: Introductionmentioning

confidence: 99%

Downregulation of miR‐133b predict progression and poor prognosis in patients with urothelial carcinoma of bladder

Chen

et al. 2016

Cancer Medicine

View full text Add to dashboard Cite

We found microRNA‐133b (miR‐133b) was downregulated in urothelial carcinoma of the bladder (UCB) tissues, and it could inhibit the proliferation and induce apoptosis in UCB cells. Consequently, we intend to explore the clinical significance of miR‐133b in UCB patients. Expression of miR‐133b in 146 UCB specimens and matched adjacent non‐neoplastic bladder tissues were measured by quantitative real‐time polymerase chain reaction. The overall survival (OS) curve and progression‐free survival (PFS) curve were plotted using the Kaplan–Meier method. Prognostic factors for OS and PFS were identified by univariate and multivariate analyses using the Cox proportional hazards regression model. The expression of miR‐133b was significantly downregulated in UCB tissues compared with those in adjacent non‐neoplastic bladder tissues (P < 0.001). Among UCB patients, low expression of miR‐133b significantly correlated with aggressive clinicopathological features. Multivariate analysis indicated that the expression of miR‐133b was the independent prognostic factors for predicting PFS (RR: 2.97; 95% CI: 1.78–6.44; P = 0.009) and OS (RR: 4.23; 95% CI: 1.51–11.8; P = 0.011) in patients with UCB. Our study demonstrated that downregulation of miR‐133b associated with aggressive clinicopathological features and predicted unfavorable prognosis in patients with UCB, might serve as feasible biomarker for clinical outcome of UCB patients after surgery and potential therapeutic target in the future.

show abstract

“…miR-124a has been also related to tumorigenesis through its modulation of the expression of the cyclin-dependent kinase 6 (CDK6) oncogene and the retinoblastoma (RB1) tumor suppressor gene [99]. miR-133b, down-regulated in a number of tumor types, including esophageal, lung, and colon cancers [100][101][102][103], targets myeloid cell leukemia 1 (MCL1, also known as BCL2L3) and BCL2-like 2 (BCL2L2) [101], oncogenic actinbinding factors like fascin homolog 1 (FSCN1) [102], and the met proto-oncogene receptor tyrosine kinase (MET) [103].…”

Section: Neurodegenerative Diseases Meet Cancers In a Mirna Worldmentioning

confidence: 99%

17 Neurodegenerative Disorders

Runge¹,

Morelli²

2011

Essentials of Clinical MR

View full text Add to dashboard Cite

Abstract:Neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD) and frontotemporal dementias (FTD), are considered distinct entities, however, there is increasing evidence of an overlap from the clinical, pathological and genetic points of view. All neurodegenerative diseases are characterized by neuronal loss and death in specific areas of the brain, for example, hippocampus and cortex for AD, midbrain for PD, frontal and temporal lobes for FTD. Loss of neurons is a relatively late event in the progression of neurodegenerative diseases that is typically preceded by other events such as metabolic changes, synaptic dysfunction and loss, neurite retraction, and the appearance of other abnormalities, such as axonal transport defects. The brain's ability to compensate for these dysfunctions occurs over a long period of time and results in late clinical manifestation of symptoms, when successful pharmacological intervention is no longer feasible. Currently, diagnosis of AD, PD and different forms of dementia is based primarily on analysis of the patient's cognitive function. It is therefore important to find non-invasive diagnostic methods useful to detect neurodegenerative diseases during early, preferably asymptomatic stages, when a pharmacological intervention is still possible. Altered expression of microRNAs (miRNAs) in many disease states, including neurodegeneration, and increasing relevance of miRNAs in biofluids in different pathologies has prompted the study of their possible application as neurodegenerative diseases biomarkers in order to identify new therapeutic targets. Here, we review what is known about the role of miRNAs OPEN ACCESSMolecules 2014, 19 6892 in the pathogenesis of neurodegeneration and the possibilities and challenges of using these small RNA molecules as a signature for neurodegenerative conditions.

show abstract

miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo

Cited by 107 publications

References 35 publications

miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2

miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2

Downregulation of miR‐133b predict progression and poor prognosis in patients with urothelial carcinoma of bladder

17 Neurodegenerative Disorders

Contact Info

Product

Resources

About